- Home
- CELU vs XGN Comparison
CELU vs XGN Comparison
Compare CELU & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- XGN
- Stock Information
- Founded
- CELU 2016
- XGN 2002
- Country
- CELU United States
- XGN United States
- Employees
- CELU N/A
- XGN N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- CELU Health Care
- XGN Health Care
- Exchange
- CELU Nasdaq
- XGN Nasdaq
- Market Cap
- CELU 40.9M
- XGN 44.7M
- IPO Year
- CELU N/A
- XGN 2019
- Fundamental
- Price
- CELU $2.46
- XGN $2.98
- Analyst Decision
- CELU
- XGN Buy
- Analyst Count
- CELU 0
- XGN 1
- Target Price
- CELU N/A
- XGN $7.00
- AVG Volume (30 Days)
- CELU 3.1M
- XGN 21.5K
- Earning Date
- CELU 11-07-2024
- XGN 11-12-2024
- Dividend Yield
- CELU N/A
- XGN N/A
- EPS Growth
- CELU N/A
- XGN N/A
- EPS
- CELU N/A
- XGN N/A
- Revenue
- CELU $42,690,000.00
- XGN $55,751,000.00
- Revenue This Year
- CELU N/A
- XGN $9.98
- Revenue Next Year
- CELU $233.89
- XGN $13.63
- P/E Ratio
- CELU N/A
- XGN N/A
- Revenue Growth
- CELU 182.02
- XGN 8.00
- 52 Week Low
- CELU $1.30
- XGN $1.30
- 52 Week High
- CELU $7.97
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- CELU 49.49
- XGN 58.94
- Support Level
- CELU $3.26
- XGN $2.62
- Resistance Level
- CELU $4.34
- XGN $2.97
- Average True Range (ATR)
- CELU 0.84
- XGN 0.21
- MACD
- CELU 0.11
- XGN 0.05
- Stochastic Oscillator
- CELU 29.59
- XGN 83.33
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.